Mammaglobin, beta-C atenin and Wnt2 expression in peripheral blood of breast cancer patients and its association with allelic variants and epigenetic silencing in APC , CDH1, GSK3b and AXIN2 genes

• Grant number: 13/00824-3
• Support Opportunities: Regular Research Grants
• Start date: May 01, 2013
• End date: April 30, 2015
• Field of knowledge: Biological Sciences - Genetics - Mutagenesis
• Principal Investigator: Catarina Satie Takahashi
• Grantee: Catarina Satie Takahashi
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil
• Associated researchers: Helio Humberto Angotti Carrara ; Jurandyr Moreira de Andrade

Abstract

Of the total number of deaths due by cancer, breast cancer is that accounts for the largest number of female deaths in Brazil, since it has a high metastatic potential, and its incidence and mortality has been increasing over the last 25 years; it is very important to find new specific markers for early diagnosis, using simple and rapid procedures. Objective: To determine the expression of genes h-MAM, CTNNB1 and WNT2 in peripheral blood of patients with breast cancer at any stage in order to compare clinical abnormalities found with a group of healthy people and determine if there is correlation between expression of these genes to disease progression, moreover, determine its association with allelic variants and epigenetic silencing of genes APC, GSK3b, CDH1 and Axin2. MATERIALS AND METHODS: Peripheral blood from 107 patients with breast cancer of different histological types and degrees and 107 healthy people (controls) who voluntarily accept to participate in the project will be collected and processed to obtain DNA and RNA. Expression levels will be assessed by RT - qPCR, allelic variants by PCR - RFLP and MSRA - PCR to identify the promoter sequences methylation. With this data we hope to contribute to a better understanding of this disease entity and serve as a subsidy for timely diagnosis and prognosis, in addition, we hope to provide strong evidence of the usefulness of h-MAM, CTNNB1 and WNT2 as markers for early diagnosis of metastatic breast cancer. (AU)